Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution of ablative fractional laser-assisted topical delivery of Vismodegib in basal cell carcinomas
2019-002545-38Phase 2Completed
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vismodegib in basal cell carcinoma (BCC) (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoints: Intra-tumoral vismodegib concentration and Biologic response via GLI mRNA level. Started Jun 2019; status: completed.
02
Drugs
vismodegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2019-002545-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002545-38.